Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Spin-Out A Neat Solution For Sanofi’s Manufacturing Millstone

Bypasses Union Objections To Downsizing

Executive Summary

Hudson finds solution for legacy sites which have dogged predecessors.

You may also be interested in...



Sanofi API Unit Expects $1bn Sales By 2022

Sanofi has announced plans to create the world’s second-largest API manufacturer to help ease European drugmakers’ dependence on supplies of raw materials from China and India.

Sanofi Highlights MS Asset After Solid Q4

The French drugmaker ended 2019 with a solid Q4 performance and news that its BTK inhibitor SAR442168 will start Phase III testing in progressive and elapsing multiple sclerosis. 

Potential For Functional Cure Opens Up With GSK’s Hepatitis B Candidate

Bepirovirsen made the hepatitis B virus undetectable in nearly 30% of patients in a Phase II study – but it remains to be seen whether this response be sustained once treatment with the novel antisense product ends.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC141720

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel